Medindia

X

Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis

Thursday, December 3, 2009 General News J E 4
Advertisement


NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Myeloma Therapeutics - US Market Trends & Analysis

http://www.reportlinker.com/p0164271/Multiple-Myeloma-Therapeutics---US-Market-Trends--Analysis.html

Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Although patients today have a broader choice of treatments than before, the objective of all the treatment therapies is to slower the growth of malignant myeloma cells rather than elimination, and offer palliative care such as, reduction in disease symptoms, such as, fatigue, anemia, bone pain, and recurrent infections, among others.

These and other market data and trends are presented in "Multiple Myeloma Therapeutics: US Market Trends & Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

MULTIPLE MYELOMA THERAPEUTICS BMR-1071

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. MARKET OVERVIEW 3

Hematological Cancer Therapies: A Prelude 3

Treatment Regimes: The Golden Rule 4

Multiple Myeloma: A Second Most Common Hematological Cancer 5

Treatment Therapies: Move Up the Learning Curve 6

Risk-Adapted Therapy: The New Norm of Future Treatment 7

New Generation Drugs in the Arsenal Against Multiple Myeloma 7

Velcade® (Bortezomib) 7

Thalomid® (Thalidomide) 7

Revlimid® (Lenalidomide) 8

Alkeran (Melphalan) 8

Doxil (Liposomal Doxorubicin) 9

Trisenox® (Arsenic trioxide) 9

Noteworthy Issues Related to Major Drugs: An Evaluation of

Pros and Cons 9

Revlimid Overtakes Thalomid: Why? 9

How Effective Will Thalomid Be in the 3rd Line Setting?

Skepticism Overflows 10

Revlimid Impedes Stem Cell Harvesting!!: What's the Truth? 10

1st & 2nd Generation Geldanamycin Analog to Do Wonders for

Myeloma Treatment 10

Other Trends & Issues 11

Approval of New Generation Drugs Push the Market Into the

Bulge Bracket 11

Growth Fundamentals Get Stronger 11

Multidrug Resistance: A Challenge to Reckon With 12

Gene Therapy Exudes Hope 12

Challenges Encountered in Clinical Trials 12

FDA's Antidotes 13

Europe Lagging Behind in Drug Approvals 14

Market Share Statistics 15

Oncology and Hematology Market 16

Drugs Approved & In Pipeline: A Review 16

Multiple Myeloma Drugs Approved by the FDA As of the Year 2008 16

Multiple Myeloma Drugs in Pipeline in the US As of the Year

2008 17

Phase III Drugs in Pipeline 17

Phase II Drugs in Pipeline 18

Phase I Drugs in Pipeline 25

Key Non-Profit Organizations in the US 29

Multiple Myeloma Research Foundation (MMRF) 29

National Coalition for Cancer Survivorship (NCCS) 29

National Marrow Donor Program (NMDP) 29

Oregon Health and Science University Cancer Institute 29

3. PRODUCT FACTS 30

Drugs 30

Lines of Treatment 30

4. CORPORATE DEVELOPMENTS 31

NICE Grants Approval for Use of Revlimid® 31

SWOG Announces Closure of Phase III Trial (S0232) for Paitents

with Multiple Myeloma 31

CytRx to Acquire Innovive 32

Launch of Epoetin alfa Hexal 32

PDL and Bristol-Myers Signs Agreement 32

MNKD and LLS Conclude Joint Research Agreement 33

MorphoSys and DSM Enter into Agreement 33

StemCyte Enters into Joint Venture with Cadila and Apollo

Hospitals in India 33

ImmunoCellular Acquires Molecular Antibody Technology 34

US House of Representatives Sanction the Hematological Cancer

Research Investment and Education Act 34

Bayer and Cell Therapeutics Enter into Mutual Agreement 34

Bristol-Myers to Take Over Kosan Biosciences 35

Bristol and PDL BioPharma Enter into Agreement 35

Gamida Cell Enters Into a Agreement with Amgen 35

Circadian Acquires Complete Stake in Vegenics 35

Takeda Acquires Millennium Pharmaceuticals 36

Fujimoto Pharmaceutical Receives Approval to Market Thalidomide 36

Celgene Obtains Health Canada Approval for Revlimid Oral

Cancer Drug 36

FDA Grants Orphan-Drug Designation to Melphalan 37

Merck Commences Phase b and Phase III Clinical Trial of

Zolinza 37

Clavis Initiates Phase II Trial of Elacytarabine 38

Gilead Sciences Commences GS 9219 Phase I Clinical Trial 38

AstraZeneca Carries Out AZD 0530 Phase II trial 38

European Commission Grants Approval of Thalidomide for

Multiple Myeloma 38

EMEA Issues Positive Opinion for Thalidomide Use in Multiple

Myeloma 38

Global Regulatory Developments for the Use of Revlimid® in

Multiple Myeloma 39

Takeda Gains FDA Approval to Promote Velcade 39

Health Canada Approves VELCADE 40

Genzyme Receives FDA Certification for Mozobil 40

Celgene's Thalidomide Pharmion Receives Marketing Authorization 41

GlaxoSmithKline Forms Alliance with OncoMed for Developing

Cancer Therapeutics 41

Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals 41

Biogen and Genentech to Jointly Develop and Commercialize New

Blood Cancer Drug 42

Aegera Therapeutics Acquires LymphoSign Inc 42

Velcade Gains Subsidy 43

Inex Pharmaceuticals Spins Off Biotechnology Business into

Tekmira Pharmaceuticals 43

MilleGen Enters into Collaboration with LFB 43

Access Pharmaceuticals to Acquire Somanta 43

TopoTarget to Acquire Apoxis SA 43

Genentech Inks Exclusive Global Licensing Agreement with

Seattle Genetics 44

Celgene Agrees to Acquisition of Pharmion 44

PerkinElmer Plans Acquisition of ViaCell 44

Favrille Announces Acquisition of Monoclonal Antibody Range

from Diversa 45

Johnson & Johnson Secures Contract worth US$112 Million 45

Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi

Biopharmaceuticals 45

Ziopharm Commences Phase II Clinical Trial of ZIO-101 46

FDA Approves Pluristem's Pre-IND Application of PLX-I 46

Merck Pharmaceuticals Commences Phase I Study for R763 Kinase

Inhibitor 46

Swissmedic Approves Celgene's REVLIMID Oral Cancer Drug 46

Celgene's REVLIMID Receives EU's Marketing Authorization 47

FDA Approves Application of Piramal's IND-P276 Multiple

Myeloma Drug 47

Millennium Pharmaceuticals and Johnson & Johnson Initiate

Velcade® Phase II Trial 47

FDA to Consider the New Drug Application Filed for Use of

Doxil® Combined with Velcade® in Patients with Multiple

Myeloma 48

Ortho Biotech Files Application with FDA for Approval of

Combination Drug DOXIL® and VELCADE® 48

Caraco's Allopurinol Receives FDA Approval 48

5. MAJOR PLAYERS 49

Amgen Inc (USA) 49

Bristol-Myers Squibb Company (USA) 49

Kosan Biosciences, Inc. (USA) 49

Celgene Corporation (USA) 49

F. Hoffmann-La Roche Ltd Switzerland) 49

Genentech, Inc. (USA) 49

Genta Incorporated (USA) 50

Millennium Pharmaceuticals (USA) 50

Ortho Biotech Products, LP (USA) 50

Seattle Genetics (USA) 50

Ziopharm Oncology, Inc. (USA) 50

6. MARKET ANALYTICS 51

EXHIBITS

Table 1: Percentage Breakdown of Hematological Cancer Cases by

Type in the US - 2008E

Table 2: Percentage Breakdown of Drugs Used in First Line

Treatment in European Multiple Myeloma Market - 2006

Table 3: Percentage Breakdown of Drugs Used in Second Line

Treatment in European Multiple Myeloma Market - 2006

Table 4: Percentage Breakdown of Drugs Used in Third Line

Treatment in European Multiple Myeloma Market - 2006

Table 5: Market Shares of Leading Companies in the US Market

for Multiple Myeloma Therapeutics - 2006

Table 6: Market Shares of Leading Companies in the US Market

for Multiple Myeloma Therapeutics - 2013P

Table 7: Market Shares of Leading Companies in the US Market

for Oncology and Hematology - 2008E

Table 8: Multiple Myeloma Therapeutics Market by Drug in the

US: 2007-2015 (Sales in US$ Million)

Table 9: Percentage Breakdown of Multiple Myeloma Therapeutics

Market by Drug in the US for the Years 2009 & 2012

Table 10: Multiple Myeloma Therapeutics Market by Line of

Treatment in the US: 2007-2015 (Sales in US$ Million)

Table 11: Percentage Breakdown of Multiple Myeloma

Therapeutics Market by Line of Treatment in the US for the

Years 2009 & 2012

COMPANIES PROFILED

To order this report:

Therapy Industry: Multiple Myeloma Therapeutics - US Market Trends & Analysis

More Market Research Report

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Arthroscopes - A World Market Re...
S
Reportlinker Adds Carbondioxide Incubators - A Glo...